|1.||Olson, Eric R: 2 articles (11/2010 - 11/2009)|
|2.||Stanton, Bruce A: 1 article (01/2015)|
|3.||Barnaby, Roxanna: 1 article (01/2015)|
|4.||Hogan, Deborah: 1 article (01/2015)|
|5.||Coutermarsh, Bonita: 1 article (01/2015)|
|6.||Jih, Kang-Yang: 1 article (03/2013)|
|7.||Hwang, Tzyh-Chang: 1 article (03/2013)|
|8.||Pettit, Rebecca S: 1 article (07/2012)|
|9.||Erlinger, S: 1 article (04/2011)|
|10.||Zha, Jiuhong: 1 article (11/2010)|
|2.||Cystic Fibrosis (Mucoviscidosis)
11/18/2010 - "We randomly assigned 39 adults with cystic fibrosis and at least one G551D-CFTR allele to receive oral VX-770 every 12 hours at a dose of 25, 75, or 150 mg or placebo for 14 days (in part 1 of the study) or VX-770 every 12 hours at a dose of 150 or 250 mg or placebo for 28 days (in part 2 of the study). "
04/01/2011 - "The authors of this work have shown that VX-770, an agent known previously to increase the activity of wild-type and G551D-CFTR cell surface protein in vitro, was able, when given orally to 39 cystic fibrosis patients during 14 and 28 days, to partially restore chloride conductance, as measured by nasal epithelium potential difference. "
11/18/2010 - "Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation."
07/01/2012 - "Search terms included ivacaftor, VX-770, VX-809, ataluren, PTC 124, CFTR modulator, and cystic fibrosis. "
03/12/2013 - "Vx-770 (Ivacaftor), a Food and Drug Administration (FDA)-approved drug for clinical application to patients with cystic fibrosis (CF), shifts the paradigm from conventional symptomatic treatments to therapeutics directly tackling the root of the disease: functional defects of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel caused by pathogenic mutations. "
|3.||Dehydration (Water Stress)
|1.||Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)
|2.||Chloride Channels (Chloride Channel)